Zealand Pharma — Juni 2025
-
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome
-
Copenhagen, Denmark, June 2, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome (SBS).
-
The submission of the MAA to the EMA for glepaglutide administered twice weekly for the treatment of SBS is based on results from a pivotal Phase 3 trial (EASE-1), supported by interim results from two ongoing long-term extension trials (EASE-2 and EASE-3) and results from a mechanistic trial (EASE-4).
-
“We are pleased to bring our potential best-in-class GLP-2 analog, glepaglutide, one step closer to patients in Europe living with short bowel syndrome with intestinal failure, who urgently need more effective and more convenient treatment options,” said David Kendall, MD, Chief Medical Officer of Zealand Pharma
-
“We believe that glepaglutide, administered twice weekly, offers meaningful potential to reduce both the burden of parenteral support and the inconvenience of daily dosing required with the only currently available GLP-2 therapy. Looking ahead, we expect to initiate the EASE-5 Phase 3 trial in the second half of the year to obtain further confirmatory safety and efficacy data on the twice weekly dosing regimen, supporting regulatory submission in the U.S.”
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1323254/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
Zealand søger godkendelse af middel til behandling af korttarmssyndrom i Europa https://proinvestor.com/investornyt/1323271/zealand-soger-godkendelse-af-middel-til-behandling-af-korttarmssyndrom-i-europa
-
Shorthandlerne skifter spor. Køb Zealand Pharma https://proinvestor.com/investornyt/1323783/shorthandlerne-skifter-spor-kob-zealand-pharma
-
Gubra indbyder til udbyttefest https://proinvestor.com/boards/126606
-
Per Hansen mener ZP kunne gøre det samme - diverse medier
-
Se link 8,24 ST.
-
sorry)
-
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1324368/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
Jeg har efter handelkrigen brød ud i USA omlagt en del af mine investringer fra aktier til obligationer men jeg har nu besluttet at jeg selektivt går tilbake mere aktivt i enkelt aktier. Jeg har derfor købt Zealand Pharma i dag og vil deltak aktivt her i chatten igen. Familien har aldrig været helt ude men er nu mere aktivt tilbake i denne aktie.
-
Godt at høre ES - dejligt at have dig tilange
-
tilbage og i den...
-
Fedmemarkedet handler primært om glp1, senere er amylin blevet kendt, men det dansk-svenske biotekselskab Pila Pharma, grundlagt af Dorte X. Gram med rødder i Novo Nordisk, udvikler en oral behandling mod type 2-diabetes og fedme baseret på en såkaldt chili-receptor. Hør mere i denne video, hvor Helge Larsen har besøg af Dorte X. Gram https://proinvestor.com/boards/126647
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1325523/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind